Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Phibro Animal Health in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Phibro Animal Health’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:25 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056280
| For the Periods Ended March 31 | Three Months / 2026 | Three Months / 2025 | Nine Months / 2026 | Nine Months / 2025 |
|---|---|---|---|---|
| Net sales | $383,543 | $347,825 | $1,121,346 | $917,518 |
| Cost of goods sold | 257,868 | 243,257 | 743,232 | 627,585 |
| Gross profit | 125,675 | 104,568 | 378,114 | 289,933 |
| Selling, general and administrative expenses | 81,022 | 71,053 | 231,875 | 213,186 |
| Operating income | 44,653 | 33,515 | 146,239 | 76,747 |
| Interest expense, net | 10,431 | 9,355 | 34,246 | 25,992 |
| Foreign currency losses (gains), net | 1,909 | (5,528) | 6,988 | 6,609 |
| Income before income taxes | 32,313 | 29,688 | 105,005 | 44,146 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phibro Animal Health's SG&A?
- Phibro Animal Health (PAHC) reported SG&A of $81.02M in Q1 2026.
- How has Phibro Animal Health's SG&A changed year-over-year?
- Phibro Animal Health's SG&A increased by 14.0% year-over-year, from $71.05M to $81.02M.
- What is the long-term trend for Phibro Animal Health's SG&A?
- Over 3 years (2022 to 2025), Phibro Animal Health's SG&A has grown at a 11.9% compound annual growth rate (CAGR), from $206.41M to $289.48M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Phibro Animal Health's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude